Reg FD Disclosure

United States Securities and Exchange Commission (the “SEC”) (the “SEC settlement”) in connection with previously disclosed SEC investigations of two former Company executives and the Company. Under the terms of the SEC settlement, the Company, without admitting or denying the findings of the SEC, consented to the entry of an administrative order that requires the Company to cease and desist from committing or causing any violations and any future violations of Sections 13(a), 13(b)(2)(A), 13(b)(2)(B), and 14(a) of the Securities Exchange Act of 1934 and Rules 12b-20, 13a-1, 14a-3, and 14a-9 thereunder. The SEC did not allege fraud by the Company. The SEC noted in its settlement order that it had taken into consideration remedial acts promptly undertaken and cooperation afforded to SEC staff by the Company. A copy of the Press Release is attached to this Current Report as Exhibit 99.1 and is incorporated herein by reference. Pursuant to the rules and regulations of the SEC, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release, dated December 12, 2017 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 12, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. By: /s/ Timothy C. Scott Timothy C. Scott President